159 related articles for article (PubMed ID: 31644441)
1. Cost-Effectiveness Analysis of Upfront SBRT for Oligometastatic Stage IV Non-Small Cell Lung Cancer Based on Mutational Status.
Kim H; Vargo JA; Ling DC; Beriwal S; Smith KJ
Am J Clin Oncol; 2019 Nov; 42(11):837-844. PubMed ID: 31644441
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of stereotactic body radiation therapy versus surgical resection for stage I non-small cell lung cancer.
Shah A; Hahn SM; Stetson RL; Friedberg JS; Pechet TT; Sher DJ
Cancer; 2013 Sep; 119(17):3123-32. PubMed ID: 23720093
[TBL] [Abstract][Full Text] [Related]
3. A cost-effectiveness analysis of consolidative local therapy in oligometastatic non-squamous non-small cell lung cancer (NSCLC).
Panje CM; Dedes KJ; Matter-Walstra K; Schwenkglenks M; Gautschi O; Siano M; Aebersold DM; Plasswilm L; Lupatsch JE;
Radiother Oncol; 2018 Nov; 129(2):257-263. PubMed ID: 30104008
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of stereotactic body radiation therapy versus video assisted thoracic surgery in medically operable stage I non-small cell lung cancer: A modeling study.
Wolff HB; Alberts L; van der Linden N; Bongers ML; Verstegen NE; Lagerwaard FJ; Hofman FN; Uyl-de Groot CA; Senan S; El Sharouni SY; Kastelijn EA; Schramel FMNH; Coupé VMH
Lung Cancer; 2020 Mar; 141():89-96. PubMed ID: 31982640
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of stereotactic body radiotherapy and surgery for medically operable early stage non small cell lung cancer.
Paix A; Noel G; Falcoz PE; Levy P
Radiother Oncol; 2018 Sep; 128(3):534-540. PubMed ID: 29706462
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of single fraction of stereotactic body radiation therapy compared with single fraction of external beam radiation therapy for palliation of vertebral bone metastases.
Kim H; Rajagopalan MS; Beriwal S; Huq MS; Smith KJ
Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):556-63. PubMed ID: 25680599
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness and Net Monetary Benefit of Durvalumab Consolidation Therapy Versus No Consolidation Therapy After Chemoradiotherapy in Stage III Non-small Cell Lung Cancer in the Italian National Health Service.
Armeni P; Borsoi L; Fornaro G; Jommi C; Grossi F; Costa F
Clin Ther; 2020 May; 42(5):830-847. PubMed ID: 32354495
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater.
She L; Hu H; Liao M; Xia X; Shi Y; Yao L; Ding D; Zhu Y; Zeng S; Shen L; Huang J; Carbone DP
Lung Cancer; 2019 Dec; 138():88-94. PubMed ID: 31655368
[TBL] [Abstract][Full Text] [Related]
9. A comparison of surgical intervention and stereotactic body radiation therapy for stage I lung cancer in high-risk patients: a decision analysis.
Puri V; Crabtree TD; Kymes S; Gregory M; Bell J; Bradley JD; Robinson C; Patterson GA; Kreisel D; Krupnick AS; Meyers BF
J Thorac Cardiovasc Surg; 2012 Feb; 143(2):428-36. PubMed ID: 22169443
[TBL] [Abstract][Full Text] [Related]
10. Cost-Effectiveness and Value of Information of Erlotinib, Afatinib, and Cisplatin-Pemetrexed for First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer in the United States.
Ting J; Tien Ho P; Xiang P; Sugay A; Abdel-Sattar M; Wilson L
Value Health; 2015 Sep; 18(6):774-82. PubMed ID: 26409604
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of EGFR mutation testing and gefitinib as first-line therapy for non-small cell lung cancer.
Narita Y; Matsushima Y; Shiroiwa T; Chiba K; Nakanishi Y; Kurokawa T; Urushihara H
Lung Cancer; 2015 Oct; 90(1):71-7. PubMed ID: 26259876
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of pembrolizumab plus chemotherapy with PD-L1 test for the first-line treatment of NSCLC.
Wan N; Zhang TT; Hua SH; Lu ZL; Ji B; Li LX; Lu LQ; Huang WJ; Jiang J; Li J
Cancer Med; 2020 Mar; 9(5):1683-1693. PubMed ID: 31945265
[TBL] [Abstract][Full Text] [Related]
13. International Cost-Effectiveness Analysis of Durvalumab in Stage III Non-Small Cell Lung Cancer.
Kareff SA; Han S; Haaland B; Jani CJ; Kohli R; Aguiar PN; Huang Y; Soo RA; Rodríguez-Perez Á; García-Foncillas J; Dómine M; de Lima Lopes G
JAMA Netw Open; 2024 May; 7(5):e2413938. PubMed ID: 38814640
[TBL] [Abstract][Full Text] [Related]
14. Cost-Effectiveness of Surgery, Stereotactic Body Radiation Therapy, and Systemic Therapy for Pulmonary Oligometastases.
Lester-Coll NH; Rutter CE; Bledsoe TJ; Goldberg SB; Decker RH; Yu JB
Int J Radiat Oncol Biol Phys; 2016 Jun; 95(2):663-72. PubMed ID: 27055395
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness analysis comparing conventional versus stereotactic body radiotherapy for surgically ineligible stage I non-small-cell lung cancer.
Mitera G; Swaminath A; Rudoler D; Seereeram C; Giuliani M; Leighl N; Gutierrez E; Dobrow MJ; Coyte PC; Yung T; Bezjak A; Hope AJ
J Oncol Pract; 2014 May; 10(3):e130-6. PubMed ID: 24643574
[TBL] [Abstract][Full Text] [Related]
16. EGFR mutation-guided use of afatinib, erlotinib and gefitinib for advanced non-small-cell lung cancer in Hong Kong - A cost-effectiveness analysis.
You JHS; Cho WCS; Ming WK; Li YC; Kwan CK; Au KH; Au JS
PLoS One; 2021; 16(3):e0247860. PubMed ID: 33647045
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France.
Chouaid C; Bensimon L; Clay E; Millier A; Levy-Bachelot L; Huang M; Levy P
Lung Cancer; 2019 Jan; 127():44-52. PubMed ID: 30642550
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of stereotactic body radiotherapy and radiofrequency ablation for medically inoperable, early-stage non-small cell lung cancer.
Sher DJ; Wee JO; Punglia RS
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):e767-74. PubMed ID: 21300476
[TBL] [Abstract][Full Text] [Related]
19. Gene-guided gefitinib switch maintenance therapy for patients with advanced EGFR mutation-positive non-small cell lung cancer: an economic analysis.
Zhu J; Li T; Wang X; Ye M; Cai J; Xu Y; Wu B
BMC Cancer; 2013 Jan; 13():39. PubMed ID: 23360224
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of second-line atezolizumab in Canada for advanced non-small cell lung cancer (NSCLC).
Ondhia U; Conter HJ; Owen S; Zhou A; Nam J; Singh S; Abdulla A; Chu P; Felizzi F; Paracha N; Sangha R
J Med Econ; 2019 Jul; 22(7):625-637. PubMed ID: 30836031
[No Abstract] [Full Text] [Related]
[Next] [New Search]
